Objective: Mindfulness-Based Stress Reduction (MBSR) therapy has been very effective intervention across worldwide. Herein we aimed to investigate the effect of MBSR intervention on anxiety, depression among breast cancer patients undergoing postoperative chemotherapy.
Methods: 225 breast cancer patients in our hospital were divided into two groups, 106 patients in the MBSR group received Mindfulness-Based Stress Reduction intervention, while 111 patients in the control group were given routine nursing. The Self-rating Anxiety Scale (SAS), self-rating depression scale (SDS), and functional assessment of cancer therapy-breast cancer (FACT-B) were used to assess the effect of MBSR intervention on breast cancer patients undergoing postoperative chemotherapy.
Results: There were significant differences in the scores of physiological statuses, social and family status, emotional status, functional status, additional attention and total score after intervention between two groups (P < .05). The difference between SDS and SAS were statistically significant between the two groups (P < .05). The score of SDS and SAS were significantly improved in the MBSR group compared with the control group (P < .05).
Conclusion: MBSR therapy could effectively improve the quality of life of patients with breast cancer patients with chemotherapy, mainly focusing on psychological aspects, while the effect of the physiological intervention was not significant.
Download full-text PDF |
Source |
---|
Breast Cancer Res
January 2025
Department of Breast Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Jiefang Road, Hangzhou, Zhejiang, China.
Background: Neoadjuvant chemotherapy (NACT) is the standard-of-care treatment for patients with locally advanced breast cancer (LABC), providing crucial benefits in tumor downstaging. Clinical parameters, such as molecular subtypes, influence the therapeutic impact of NACT. Moreover, severe adverse events delay the treatment process and reduce the effectiveness of therapy.
View Article and Find Full Text PDFBMC Cancer
January 2025
Division of Clinical Research and Technological Development, Brazilian National Cancer Institute, 37 Andre Cavalcanti Street, 5th floor, Annex Building, 20231050, Rio de Janeiro, Brazil.
Background: Breast cancer (BC) has exhibited varied epidemiological trends based on distinct age categories. This research aimed to explore the incidence and mortality rates of BC within pre-defined age groups in the Brazilian population.
Methods: BC incidence trends were assessed from 2010 to 2015 using Brazilian Population-Based Cancer Registries, employing age-standardized ratios and annual average percentage change (AAPC).
BMC Med Imaging
January 2025
Electronics and Communications, Arab Academy for Science, Heliopolis, Cairo, 2033, Egypt.
Invasive breast cancer diagnosis and treatment planning require an accurate assessment of human epidermal growth factor receptor 2 (HER2) expression levels. While immunohistochemical techniques (IHC) are the gold standard for HER2 evaluation, their implementation can be resource-intensive and costly. To reduce these obstacles and expedite the procedure, we present an efficient deep-learning model that generates high-quality IHC-stained images directly from Hematoxylin and Eosin (H&E) stained images.
View Article and Find Full Text PDFBreast Cancer Res Treat
January 2025
University of Pittsburgh School of Medicine (Center for Clinical Genetics and Genomics), Pittsburgh, PA, USA.
Breast Cancer Res Treat
January 2025
Department of Public Health Sciences, University of Virginia, 560 Ray C Hunt Dr., Room 2107, Charlottesville, VA, USA.
Purpose: While previous research has highlighted treatment delay inequities in early-stage breast cancer and identified potential contributing factors, there is limited research on disparities in treatment delays for metastatic breast cancer (MBC). This study investigates these disparities in MBC treatment initiation, aiming to identify key factors crucial for improving timely access to care.
Method: Nationwide Flatiron Health electronic health records-derived deidentified database, including females aged 18+ diagnosed with either De novo or relapsed MBC in the U.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!